KR20080110681A - 안정적 에멀젼 조제물 - Google Patents

안정적 에멀젼 조제물 Download PDF

Info

Publication number
KR20080110681A
KR20080110681A KR1020087027937A KR20087027937A KR20080110681A KR 20080110681 A KR20080110681 A KR 20080110681A KR 1020087027937 A KR1020087027937 A KR 1020087027937A KR 20087027937 A KR20087027937 A KR 20087027937A KR 20080110681 A KR20080110681 A KR 20080110681A
Authority
KR
South Korea
Prior art keywords
alkyl
acid
calcium
oil
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020087027937A
Other languages
English (en)
Korean (ko)
Inventor
아누라다 고어
앤 나브라틸
세샤드리 니르반난
크리스토퍼 더블유. 스판케이크
로제 자농
Original Assignee
암겐 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암겐 인코포레이티드 filed Critical 암겐 인코포레이티드
Publication of KR20080110681A publication Critical patent/KR20080110681A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020087027937A 2006-04-20 2007-04-20 안정적 에멀젼 조제물 Withdrawn KR20080110681A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79382506P 2006-04-20 2006-04-20
US60/793,825 2006-04-20

Publications (1)

Publication Number Publication Date
KR20080110681A true KR20080110681A (ko) 2008-12-18

Family

ID=38537687

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087027937A Withdrawn KR20080110681A (ko) 2006-04-20 2007-04-20 안정적 에멀젼 조제물

Country Status (14)

Country Link
US (1) US8779004B2 (enExample)
EP (1) EP2010150A2 (enExample)
JP (1) JP5199239B2 (enExample)
KR (1) KR20080110681A (enExample)
CN (1) CN101437490A (enExample)
AU (1) AU2007240317B2 (enExample)
BR (1) BRPI0710814A2 (enExample)
CA (1) CA2648939C (enExample)
CR (1) CR10384A (enExample)
EA (1) EA200802166A1 (enExample)
MX (1) MX2008013339A (enExample)
NO (1) NO20084368L (enExample)
WO (1) WO2007124465A2 (enExample)
ZA (1) ZA200808773B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082427A1 (en) * 2011-11-30 2013-06-06 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
WO2014142517A1 (ko) * 2013-03-12 2014-09-18 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
WO2017122881A1 (ko) * 2016-01-12 2017-07-20 (주)노터스생명과학 포스파티딜콜린을 유효성분으로 포함하는 신장질환 예방 또는 치료용 약학 조성물
KR20170132566A (ko) * 2016-05-24 2017-12-04 주식회사 고려비엔피 항생제의 서방형 수의학적 조성물 및 이의 제조방법
KR20200036143A (ko) * 2018-09-27 2020-04-07 한국화학연구원 자가미세유화 약물전달시스템을 이용한 난용성 약물의 약학적 제제

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US20080027052A1 (en) * 2006-07-10 2008-01-31 Sharon Moe Methods for treating cystic kidney disease
WO2008075173A2 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
CA2719256A1 (en) * 2008-03-28 2009-10-01 Amgen Inc. Methods of treating epithelial injury
JP5468221B2 (ja) * 2008-08-04 2014-04-09 株式会社 メドレックス 難溶性薬物の静注用分散製剤
WO2010042642A1 (en) * 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
US9012511B2 (en) * 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
WO2012039768A2 (en) * 2010-09-24 2012-03-29 Texas Southern University Itraconazole formulations
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
US20120213855A1 (en) * 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
EP2858513B1 (en) * 2012-06-07 2016-11-23 Cargill, Incorporated Pumpable fat compositions, use in feed and method for reducing their viscosity.
US9212209B2 (en) * 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
CN102895187B (zh) * 2012-09-13 2015-05-06 西安力邦制药有限公司 注射用本芴醇脂肪乳的制备及其在疟疾治疗中的应用
EA028569B1 (ru) * 2012-10-24 2017-12-29 Карджилл, Инкорпорейтед Композиция эмульгатора, содержащего фосфолипиды
CN103142477B (zh) * 2013-04-08 2015-09-30 薛巍 一种缓释秋水仙碱的含纳米载体微乳制剂的制备方法
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
CN106714787A (zh) * 2014-09-25 2017-05-24 富士胶片株式会社 含丙泊酚的水包油型乳液组合物及其制造方法
MX384605B (es) 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
ES3036518T3 (en) 2015-10-16 2025-09-19 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
CN105769765A (zh) * 2016-03-22 2016-07-20 辅必成（上海）医药科技有限公司 己酸羟孕酮脂肪乳注射液
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
CN109200024A (zh) * 2017-07-07 2019-01-15 江苏恒瑞医药股份有限公司 西那卡塞药物组合物及其医药用途
CN109953979A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 西那卡塞药物组合物及其医药用途
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
AU2019370565A1 (en) * 2018-11-02 2021-06-24 Ampersand Biopharmaceuticals, Inc. Management of risk of cation overload and electrolyte imbalance with topically applied buffers
US12441745B2 (en) 2019-02-12 2025-10-14 Radius Pharmaceuticals, Inc. Processes and compounds
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics
CN115554261A (zh) * 2021-07-02 2023-01-03 杭州中美华东制药有限公司 一种包含西那卡塞的组合物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR511940A (fr) 1916-12-08 1921-01-07 Rene Emile Trottier Dispositif pour la commande des appareils destinés au classement ou à la séparation des matières solides de tous genres
JPS60258110A (ja) * 1984-06-05 1985-12-20 Daigo Eiyou Kagaku Kk 静脈注射可能なプロゲステロン乳化注射液
AU702629B2 (en) 1991-08-23 1999-02-25 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
DE69233586T2 (de) 1991-08-23 2006-09-28 NPS Pharmaceuticals, Inc., Salt Lake City Kalzium-Rezeptor aktive Verbindungen
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
AU3777093A (en) 1993-02-23 1994-09-14 Brigham And Women's Hospital Calcium receptor-active molecules
EP1275635A1 (en) * 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
JP4117506B2 (ja) * 1996-05-01 2008-07-16 エヌピーエス ファーマシューティカルズ インコーポレイテッド 無機イオン活性化合物
EP1258471B1 (en) 1996-05-01 2007-01-24 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
WO1998001417A1 (en) * 1996-07-08 1998-01-15 Kirin Beer Kabushiki Kaisha Calcium receptor-active compounds
TW483881B (en) * 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
US6045824A (en) 1997-09-18 2000-04-04 Skyepharma Inc. Sustained-release liposomal anesthetic compositions
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
CN1221249C (zh) * 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 普鲁泊福的可注射水分散体
AU760889B2 (en) * 1998-10-14 2003-05-22 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
FR2809396B1 (fr) * 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
WO2001097779A2 (en) * 2000-06-16 2001-12-27 Rtp Pharma Inc. Improved injectable dispersions of propofol
FR2812875B1 (fr) * 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6916956B2 (en) * 2000-08-11 2005-07-12 Japan Tobacco, Inc. Calcium receptor antagonist
FR2820136A1 (fr) 2001-01-26 2002-08-02 Aventis Pharma Sa Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
PL382706A1 (pl) 2002-08-26 2007-11-26 Takeda Pharmaceutical Company Limited Związek modulujący receptor wapnia i jego zastosowanie
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
JPWO2004052354A1 (ja) * 2002-12-06 2006-04-06 株式会社大塚製薬工場 プロポフォール含有脂肪乳剤
PE20050460A1 (es) 2003-04-23 2005-07-08 Japan Tobacco Inc COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
CN1225242C (zh) * 2003-05-21 2005-11-02 浙江天皇药业有限公司 一种抗肿瘤药物毛兰素脂肪乳剂及其制备方法
CA2527203C (en) * 2003-05-28 2010-08-17 Japan Tobacco Inc. Casr antagonist
PL1648413T3 (pl) * 2003-07-23 2010-03-31 Theravance Inc Kompozycje farmaceutyczne zawierające jako składnik czynny krótko działający środek uspokajający i usypiający
CA2601669A1 (en) * 2005-03-17 2006-09-28 Amgen Inc. Methods of decreasing calcification
FR2885129B1 (fr) * 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
EP1882684B1 (en) 2005-05-19 2014-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
CA2620469C (en) 2005-09-02 2014-04-01 Amgen Inc. Methods of modulating intestinal fluid balance
WO2008075173A2 (en) 2006-12-15 2008-06-26 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082427A1 (en) * 2011-11-30 2013-06-06 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
US9623087B2 (en) 2011-11-30 2017-04-18 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
US9675675B2 (en) 2011-11-30 2017-06-13 3M Innovative Properties Company Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
US10154957B2 (en) 2011-11-30 2018-12-18 3M Innovative Properties Company Microneedle device having a peptide therapeutic agent and an amino acid and methods of making and using the same
WO2014142517A1 (ko) * 2013-03-12 2014-09-18 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
US10265333B2 (en) 2013-03-12 2019-04-23 Aribio Co., Ltd. Lipid nanomaterial containing lysophosphatidylcholine or derivative thereof and method for preparing same
WO2017122881A1 (ko) * 2016-01-12 2017-07-20 (주)노터스생명과학 포스파티딜콜린을 유효성분으로 포함하는 신장질환 예방 또는 치료용 약학 조성물
KR20170132566A (ko) * 2016-05-24 2017-12-04 주식회사 고려비엔피 항생제의 서방형 수의학적 조성물 및 이의 제조방법
KR20200036143A (ko) * 2018-09-27 2020-04-07 한국화학연구원 자가미세유화 약물전달시스템을 이용한 난용성 약물의 약학적 제제

Also Published As

Publication number Publication date
MX2008013339A (es) 2009-01-26
NO20084368L (no) 2008-11-17
CN101437490A (zh) 2009-05-20
ZA200808773B (en) 2009-07-29
CA2648939A1 (en) 2007-11-01
WO2007124465A2 (en) 2007-11-01
US8779004B2 (en) 2014-07-15
EA200802166A1 (ru) 2009-06-30
JP5199239B2 (ja) 2013-05-15
CR10384A (es) 2008-11-11
US20070249520A1 (en) 2007-10-25
CA2648939C (en) 2014-07-08
AU2007240317B2 (en) 2012-11-29
JP2009534425A (ja) 2009-09-24
AU2007240317A1 (en) 2007-11-01
WO2007124465A3 (en) 2008-04-10
BRPI0710814A2 (pt) 2011-08-16
EP2010150A2 (en) 2009-01-07

Similar Documents

Publication Publication Date Title
US8779004B2 (en) Stable emulsion formulations
RU2642234C2 (ru) Композиции антагонистов нейрокинина-1 для внутривенного введения
RU2678433C2 (ru) Депо-составы гидрофобного активного ингредиента и способы их получения
RU2390331C2 (ru) Жидкие депо-препараты
RU2632433C2 (ru) Липидный преконцентрат с замедленным высвобождением фармакологически активного вещества и фармацевтическая композиция, содержащая его
KR101267901B1 (ko) 프로스타글란딘 ｅ₁을 포함하는 에멀션 조성물
KR102924306B1 (ko) 건강관리 제품을 위한 계면활성제
CA2809022C (en) Phospholipid depot
JP4384409B2 (ja) バイオアベイラビリティが増加したフェンレチニドの医薬組成物、およびその使用方法
BRPI0707421A2 (pt) composições farmaceuticas de succinato de vitamina e estabilizada, métodos para sua preparação e uso
JP7457727B2 (ja) 徐放性脂質前製剤およびそれを含む脂質溶液の形態の徐放性注射用医薬組成物
KR102771577B1 (ko) 3α-에티닐-3β-하이드록시안드로스탄-17-온 옥심의 약학적 제형
US5677341A (en) Emulsion suitable for administering a sphingolipid
DE60225154T2 (de) Neues selbstemulgierendes arzneimittelfreisetzungssystem
RU2861060C2 (ru) Новые пероральные жидкие композиции энзалутамида и способ их изготовления

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081114

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid